Review article: Addressing risk factors in chronic kidney disease mineral and bone disorder: Can we influence patient‐level outcomes?
- 22 June 2009
- journal article
- review article
- Published by Wiley in Nephrology
- Vol. 14 (4), 416-427
- https://doi.org/10.1111/j.1440-1797.2009.01114.x
Abstract
Chronic kidney disease mineral and bone disorder (CKD-MBD), characterized by disturbances of calcium/phosphate/parathyroid hormone, bone abnormalities and vascular and soft tissue calcification, is highly prevalent in CKD and is a strong, independent predictor of bone fracture, cardiovascular disease and death. Clinical practice guidelines, such as the Kidney Disease Outcomes Quality Initiative (KDOQI) and Caring for Australasians with Renal Insufficiency (CARI), support the use of phosphate binders, vitamin D compounds and calcimimetics for treatment of CKD-MBD and recommend stringent targets for serum calcium, phosphate and parathyroid hormone. However, these recommendations are based primarily on the results of observational cohort studies and randomized controlled trials employing surrogate outcome measures. The aim of this paper is to review the available evidence addressing whether therapeutic strategies targeting CKD-MBD and its surrogate outcome measures appreciably influence patient-level outcomes ('hard' clinical end-points).Keywords
This publication has 84 references indexed in Scilit:
- Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trialInternational Urology and Nephrology, 2008
- CKD-MBD: impact on management of kidney diseaseClinical and Experimental Nephrology, 2007
- Magnesium Carbonate Is an Effective Phosphate Binder for Chronic Hemodialysis Patients: A Pilot StudyJournal of Renal Nutrition, 2007
- Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patientsKidney International, 2007
- Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patientsKidney International, 2007
- Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysisNephrology, 2007
- Calcium abnormalities of dialysis patientsJournal of Bone and Mineral Metabolism, 2006
- Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administrationKidney International, 2005
- Aluminum Intoxication from Aluminum-Containing Phosphate Binders in Children with Azotemia Not Undergoing DialysisNew England Journal of Medicine, 1984